-
公开(公告)号：US20160215258A1
公开(公告)日：2016-07-28
申请号：US14913707
申请日：2014-09-03
发明人： Risa OKAIRI , Masuhiro NISHIMURA , Tamaki WADA
IPC分类号： C12N5/074
CPC分类号： C12N5/0607 , A61K35/28 , C12N5/0663 , C12N2506/1353 , C12N2506/1384
摘要： An object of the present invention is to provide a method capable of inexpensively and conveniently preparing cells having pluripotency and a very low risk of tumorigenic transformation. The cells having pluripotency and a very low risk of tumorigenic transformation can be prepared by suspension-culturing mammalian mesenchymal stem cells such as human mesenchymal stem cells from bone marrow (hMSC-BM) and human adipose tissue-derived mesenchymal stem cells (hAT-MSC) (also referred to as “human adipose-derived stem cells [hADSC]”), 7 types of human adherent mature cells (human hepatocyte cells [hHEP cells], human umbilical vein endothelial cells [HUVEC cells], human dermal lymphatic microvascular endothelial cells [HMVEC cells], human epidermal keratinocyte cells [NHEK cells], human bronchial epithelial cells [NHBE cells], human melanocyte cells [NHEM cells], and human smooth muscle cells [UASMC cells]), and 3 types of human adherent precursor cells (human dermal fibroblast cells [NHDF cells], human skeletal muscle myoblast cells [HSMM cells], and human osteoblast cells [NHOst cells]) to form cell masses (spheroids).
摘要翻译： 本发明的目的是提供一种能够廉价且方便地制备具有多能性和非常低的致瘤转化风险的细胞的方法。 具有多能性和非常低的致瘤转化风险的细胞可以通过悬浮培养哺乳动物间充质干细胞例如来自骨髓的人间充质干细胞（hMSC-BM）和人脂肪组织来源的间充质干细胞（hAT-MSC ）（也称为“人类脂肪干细胞[hADSC]”），7种人贴壁成熟细胞（人肝细胞细胞[hHEP细胞]，人脐静脉内皮细胞[HUVEC细胞]，人皮肤淋巴微血管内皮 细胞[HMVEC细胞]，人表皮角化细胞[NHEK细胞]，人支气管上皮细胞[NHBE细胞]，人黑素细胞细胞[NHEM细胞]和人平滑肌细胞[UASMC细胞]）和3种人粘附前体 细胞（人真皮成纤维细胞[NHDF细胞]，人骨骼肌成肌细胞[HSMM细胞]和人成骨细胞[NHOst细胞]）形成细胞团（球状体）。
-
公开(公告)号：US20230082974A1
公开(公告)日：2023-03-16
申请号：US17793611
申请日：2021-01-20
发明人： Koji AZUMA , Masuhiro NISHIMURA , Naho IIZUKA , Hirofumi TAMURA
摘要： The present invention provides an improved method for producing pancreatic islet-containing capsules.
A method for producing pancreatic islet-containing capsules, comprising the steps of:
(a) preparing a sodium alginate solution A containing pancreatic islets at a concentration of 10,000 IEQ/mL or more;
(b) adding the sodium alginate solution to a divalent cation solution dropwise, and collecting gelled particles;
(c) adding the particles collected in step (b) to a poly-L-ornithine solution A, followed by stirring and then collecting particles;
(d) adding the particles collected in step (c) to a sodium alginate solution B, followed by stirring and then collecting particles; and
(e) adding the particles collected in step (d) to a sodium citrate solution, followed by stirring and then collecting particles.-
公开(公告)号：US20210369922A1
公开(公告)日：2021-12-02
申请号：US17403232
申请日：2021-08-16
发明人： Tomonori Yano , Atsushi Ohhata , Toshihiro Goto , Yuji Hiraki
摘要： The purpose of the present invention is to provide a viscoelastic composition having excellent operability, which is suitable for use in securing the field of view of an endoscope when opaque dark-colored liquid accumulates inside a canal and obstructs the field of view of the endoscope, the viscoelastic composition securing the field of view by pushing the liquid aside, and to provide a method for securing the field of view of an endoscope using the viscoelastic composition. The viscoelastic composition for securing the field of view of an endoscope comprises a substance having viscoelastic properties and water, preferably has a hardness of 550 N/m2 or less, a viscosity (25° C.) of 200 to 2,000 mPa·s, and a loss tangent of 0.6 or less, and more preferably has an electrical conductivity of 250 μS/cm or less. The method for securing the field of view of an endoscope comprises feeding the viscoelastic composition from a proximal part of the endoscope, through a channel, into a distal part of the endoscope.
-
公开(公告)号：US20210161143A1
公开(公告)日：2021-06-03
申请号：US17258579
申请日：2019-07-12
发明人： Kaoru IMAI , Hisae NISHIOKA , Akihumi HAGI , Shinji ODA , Kazumasa HASHIMOTO , Motoya KIKUCHI
摘要： An antiseptic composition with a more extended applicable range by further enhancing the efficacy of olanexidine gluconate, which has been used as a highly safe dermal bactericidal disinfectant, and extending antibacterial spectrum. The antiseptic composition includes and has a more extended bactericidal spectrum than conventional disinfectants.
-
公开(公告)号：US20210121417A1
公开(公告)日：2021-04-29
申请号：US16605363
申请日：2018-04-10
发明人： Takuya NII , Akifumi HAGI , Yoshie TSUBOTANI
IPC分类号： A61K31/155 , A61K9/08 , A61K47/34 , A61P29/00
摘要： An object of the present invention is to provide a composition that can be used as a novel anti-inflammatory agent. An inflammation such as stomatitis, oral mucositis, gingivitis, or pneumonia can be ameliorated and/or prevented by using a composition comprising olanexidine or a pharmacologically acceptable salt thereof. The composition of the present invention preferably further comprises a poloxamer which is a block copolymer consisting of a chain of polyoxypropylene (POP) and two chains of polyoxyethylene (POE) flanking the POP.
-
公开(公告)号：US10961493B2
公开(公告)日：2021-03-30
申请号：US15743913
申请日：2016-07-14
IPC分类号： C12M1/00 , A61K35/28 , C09D127/18 , C09D127/20 , C09D129/10 , C12N5/0775
摘要： When mammal cells are administered by using a container whose surface in contact with the mammal cells is formed of a fluororesin material at least partially having a —CF3 terminal group or a container whose surface in contact with the mammal cells is formed of a fluororesin material having a total number of non-fluorinated group terminals and —CF2H group terminals in the fluororesin of 70 or less per 1×106 carbon atoms, or mammal cells are stored or cultured in such a container, the cell adhesion on the container inner surface and the cell survival rate reduction can effectively be suppressed. Therefore, by using these containers, a mammal cell-containing liquid having a high concentration and a high proportion of living cells can be administered, stored or prepared, which contributes to regenerative medicine using the mammal cell-containing liquid (suspension liquid).
-
公开(公告)号：US20200282005A1
公开(公告)日：2020-09-10
申请号：US16756499
申请日：2018-10-19
发明人： Namiki FUJII , Yuichiro YOSHIOKA , Tatsuru FUKUDA
摘要： The purpose of the present invention is to provide an adhesion prevention material capable of exhibiting excellent adhesion preventive effect. This adhesion prevention material concurrently uses: (A) a peptide (A-1) having an amino acid sequence-(X-Pro-Y)n-[wherein X represents an arbitrary defined amino acid, Pro represents proline, Y represents hydroxyproline or proline, and n is an integer between 1 and 10] and/or a peptide (A-2) having an amino acid sequence-(Pro-Y)m-[wherein Pro represents proline, Y represents hydroxyproline or proline, and m is an integer between 1-10]; and (B) a gelatin gel. This adhesion prevention material exhibits a dramatically enhanced adhesion preventive effect as compared with the case where the abovementioned components are used individually, and in particular, has a markedly superior effect against adhesion of tendons.
-
公开(公告)号：US20190142862A1
公开(公告)日：2019-05-16
申请号：US16308701
申请日：2017-06-09
发明人： Kazuo HINO , Naoyuki ENDO , Sho MIYATAKE
IPC分类号： A61K31/732 , A61P3/02 , A61K9/08 , A23L33/125 , A61P1/12 , A23L33/16 , A61K31/716 , A61K38/17 , A61K33/42 , A61K36/899 , A61K31/715
CPC分类号： A61K31/732 , A23L33/10 , A23L33/125 , A23L33/16 , A23V2002/00 , A61K9/08 , A61K31/215 , A61K31/70 , A61K31/715 , A61K31/716 , A61K33/00 , A61K33/42 , A61K35/12 , A61K35/60 , A61K36/28 , A61K36/286 , A61K36/31 , A61K36/63 , A61K36/899 , A61K38/02 , A61K38/1709 , A61P1/12 , A61P3/02 , A61P43/00
摘要： It is an object of the present invention to provide a nutritional composition for preventing diarrhea enabling ingestion or administration of nutritional ingredients while effectively preventing diarrhea, and is capable of stably keeping the viscosity when stored in a liquid form. A nutritional composition that is prepared by selecting a pectin having a degree of esterification of 10 to 30%, a degree of amidation of 0 to 25%, and a degree of free acids of 64% or more and less than 85% among pectins, and mixing the selected pectin with lipid, carbohydrate and protein, enables ingestion or administration of nutritional ingredients while effectively preventing diarrhea, and is capable of stably keeping the viscosity when stored in a liquid form.
-
公开(公告)号：US20190000783A1
公开(公告)日：2019-01-03
申请号：US15781424
申请日：2016-11-30
发明人： Mari SHIOZAKI , Ryohei TSUBAKIYAMA , Motoya KIKUCHI , Kaoru IMAI , Akifumi HAGI
IPC分类号： A61K31/155 , A61K47/18 , A61K47/20 , A61K47/12 , A61P31/04
摘要： It is to provide a disinfectant liquid which enables easy identification of the application sites in preoperative skin disinfection and the like, where the liquid is obtained by coloring an aqueous solution of olanexidine gluconate which is a colorless and transparent liquid. A disinfectant liquid comprises olanexidine gluconate, a coloring agent such as Sunset Yellow FCF, an alkyl dimethylamine oxide such as lauryl dimethylamine oxide, and optionally one or more surfactants other than alkyl dimethylamine oxide such as polyoxyethylene alkyl ether including lauromacrogol and polyoxyethylene polyoxypropylene alkyl ether including polyoxyethylene(20) polyoxypropylene(4) cetyl ether. The disinfectant liquid enables easy identification of the application sites in preoperative skin disinfection and the like.
-
公开(公告)号：US20180201890A1
公开(公告)日：2018-07-19
申请号：US15743913
申请日：2016-07-14
IPC分类号： C12M1/00 , C12N5/0775 , C09D127/18 , C09D127/20 , C09D129/10 , A61K35/28
CPC分类号： C12M23/20 , A61K35/28 , C09D127/18 , C09D127/20 , C09D129/10 , C12M23/14 , C12N5/0663
摘要： When mammal cells are administered by using a container whose surface in contact with the mammal cells is formed of a fluororesin material at least partially having a —CF3 terminal group or a container whose surface in contact with the mammal cells is formed of a fluororesin material having a total number of non-fluorinated group terminals and —CF2H group terminals in the fluororesin of 70 or less per 1×106 carbon atoms, or mammal cells are stored or cultured in such a container, the cell adhesion on the container inner surface and the cell survival rate reduction can effectively be suppressed. Therefore, by using these containers, a mammal cell-containing liquid having a high concentration and a high proportion of living cells can be administered, stored or prepared, which contributes to regenerative medicine using the mammal cell-containing liquid (suspension liquid).
-
-
-
-
-
-
-
-
-
搜索结果
243 条记录 (耗时 0.031 秒)